Low-temperature electrocautery reduces adverse effects from secondary cardiac implantable electronic device procedures: Insights from the WRAP-IT trial.

Adverse events Cardiac implantable electronic device Implantable cardioverter-defibrillator Lead-related complications Low-temperature electrocautery Pacemaker Procedure-related complications

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
07 2021
Historique:
received: 11 01 2021
revised: 08 03 2021
accepted: 21 03 2021
pubmed: 31 3 2021
medline: 11 2 2022
entrez: 30 3 2021
Statut: ppublish

Résumé

Cardiac device procedures require tissue dissection to free existing device lead(s). Common techniques include blunt dissection, standard electrocautery, and low-temperature electrocautery (PlasmaBlade, Medtronic); however, data on the type of electrosurgical tool used and the development of procedure- or lead-related adverse events are limited. The purpose of this study was to determine whether standard or low-temperature electrocautery impacts the development of an adverse event. We evaluated patients enrolled in WRAP-IT (Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial) undergoing cardiac implantable electronic device (CIED) revision, upgrade, or replacement. All adverse events were adjudicated by an independent physician committee. Data were analyzed using Cox proportional hazard regression modeling. In total, 5641 patients underwent device revision/upgrade/replacement. Electrocautery was used in 5205 patients (92.3%) (mean age 70.6 ± 12.7 years; 28.8% female), and low-temperature electrocautery was used in 1866 patients (35.9%). Compared to standard electrocautery, low-temperature electrocautery was associated with a 23% reduction in the incidence of a procedure- or lead-related adverse event through 3 years of follow up (hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.65-0.91; P = .002). After controlling for the number of active leads, degree of capsulectomy, degree of lead dissection, and renal dysfunction, low-temperature electrocautery was associated with a 32% lower risk of lead-related adverse events (HR 0.68; 95% CI 0.52-0.89; P = .004). These effects were consistent across a spectrum of lead-related adverse event types. This study represents one of the largest assessments of electrocautery use in patients undergoing CIED revision, upgrade, or replacement procedures. Compared to standard electrocautery, low-temperature electrocautery significantly reduces adverse effects from these procedures.

Sections du résumé

BACKGROUND
Cardiac device procedures require tissue dissection to free existing device lead(s). Common techniques include blunt dissection, standard electrocautery, and low-temperature electrocautery (PlasmaBlade, Medtronic); however, data on the type of electrosurgical tool used and the development of procedure- or lead-related adverse events are limited.
OBJECTIVE
The purpose of this study was to determine whether standard or low-temperature electrocautery impacts the development of an adverse event.
METHODS
We evaluated patients enrolled in WRAP-IT (Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial) undergoing cardiac implantable electronic device (CIED) revision, upgrade, or replacement. All adverse events were adjudicated by an independent physician committee. Data were analyzed using Cox proportional hazard regression modeling.
RESULTS
In total, 5641 patients underwent device revision/upgrade/replacement. Electrocautery was used in 5205 patients (92.3%) (mean age 70.6 ± 12.7 years; 28.8% female), and low-temperature electrocautery was used in 1866 patients (35.9%). Compared to standard electrocautery, low-temperature electrocautery was associated with a 23% reduction in the incidence of a procedure- or lead-related adverse event through 3 years of follow up (hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.65-0.91; P = .002). After controlling for the number of active leads, degree of capsulectomy, degree of lead dissection, and renal dysfunction, low-temperature electrocautery was associated with a 32% lower risk of lead-related adverse events (HR 0.68; 95% CI 0.52-0.89; P = .004). These effects were consistent across a spectrum of lead-related adverse event types.
CONCLUSION
This study represents one of the largest assessments of electrocautery use in patients undergoing CIED revision, upgrade, or replacement procedures. Compared to standard electrocautery, low-temperature electrocautery significantly reduces adverse effects from these procedures.

Identifiants

pubmed: 33781980
pii: S1547-5271(21)00297-6
doi: 10.1016/j.hrthm.2021.03.033
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1142-1150

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Suneet Mittal (S)

Valley Health System, Ridgewood, New Jersey. Electronic address: MITTSU@Valleyhealth.com.

Bruce L Wilkoff (BL)

Cleveland Clinic, Cleveland Ohio.

Jeanne E Poole (JE)

University of Washington School of Medicine, Seattle, Washington.

Charles Kennergren (C)

Sahlgrenska University Hospital, Göteborg, Sweden.

David J Wright (DJ)

Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Brett J Berman (BJ)

Chula Vista Cardiac Center, Chula Vista, California.

David Riggio (D)

Arizona Arrhythmia Consultants, Scottsdale, Arizona.

Darius P Sholevar (DP)

Virtua Health System, Camden, New Jersey.

Joaquin Martinez-Arraras (J)

Amarrillo Heart Group, Amarillo, Texas.

Jean B Moubarak (JB)

Hamot Medical Center, Erie, Pennsylvania.

Robert D Schaller (RD)

University of Pennsylvania, Philadelphia, Pennsylvania.

John C Love (JC)

Maine Medical Center, Portland, Maine.

Robert A Pickett (RA)

Saint Thomas Research Institute, LLC Thomas, Nashville, Tennessee.

Francois Philippon (F)

Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canada.

Zayd Eldadah (Z)

MedStar Heart and Vascular Institute, Washington, DC.

Jeffrey D Lande (JD)

Medtronic, Mounds View, Minnesota.

Daniel R Lexcen (DR)

Medtronic, Mounds View, Minnesota.

Reece Holbrook (R)

Medtronic, Mounds View, Minnesota.

Khaldoun G Tarakji (KG)

Cleveland Clinic, Cleveland Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH